✨ Medicines Notices




MARCH

NEW ZEALAND GAZETTE

Health

Medicines Act 1981

Corrigendum

Consent to the Distribution of New Medicines

In the notice published in the New Zealand Gazette, 15 December 1994, No. 135, page 4428, notice No. 9144, (i) for the word "methylprednisole" in the thirteenth line, replace the word "methylprednisolone"; and (ii) for the strength "50 mg/ml in 0.4 ml" in the fourteenth line, replace the strength "50 mg/ml in 0.8 ml". This in respect of the product Promedrol.

Dated this 28th day of February 1995.

DAVID SMYTH, Acting Director-General of Health, pursuant to the delegation given by the Minister of Health on the 25th day of June 1993.

oi649


Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Atracurium besylate 25 mg in 2.5 ml, 50 mg in 5 ml Injection Wellcome Foundation Limited, Temple Hill, Dartford, Kent, United Kingdom Tracrium
Idarubicin 5 mg, 10 mg, 25 mg Capsules Pharmacia, Nerviano, Milan, Italy Zavedos
Tenoxicam 20 mg, 40 mg Powder for injection (glass vial and diluent) F Hoffmann-La Roche Limited, Basle, Switzerland Tilcotil
Glyceryl trinitrate 0.4 mg per spray Oral metered spray CCL Industries Limited, Runcorn, England and G Pohl Boskamp GmbH & Co., Hohenlockstedt, Germany Nitrolingual pumpspray
Malathion 0.5% w/w Liquid (topical) Simco Limited, Vale, Guernsey, Channel Islands Derbac-M
Cyclosporin A 25 mg, 50 mg, 100 mg Note: Not to be marketed as substitutable for Sandimmun as if the two (2) products were bioequivalent Capsules Sandoz Pharma Limited, Basle, Switzerland Sandimmun-Neoral
Cyclosporin A 100 mg/ml in 20 ml and 50 ml Note: Not to be marketed as substitutable for Sandimmun as if the two (2) products were bioequivalent Solution (oral) Sandoz Pharma Limited, Basle, Switzerland Sandimmun-Neoral
Simvastatin 5 mg, 10 mg, 20 mg and 40 mg Tablets Merck & Co Inc., Sumneytown Pike, West Point, Pennsylvania, United States of America and Merck Sharp & Dohme (Aust) Pty Limited, South Granville, New South Wales, Australia Zocor
Pravastatin sodium 5 mg, 10 mg and 20 mg Tablets Bristol-Myers Squibb Pharmaceuticals Pty Limited, Noble Park, Victoria, Australia Lipostat
Cefpodoxime proxetil 100 mg Tablet Roussel-Uclaf Usiphar Production Unit, Compeigne, France Orelox
Interferon alpha-2a 3, 4.5, 6, 9 and 18 million IU Powder for injection and diluent F Hoffmann-La Roche Limited, Basle, Switzerland Roferon-A

Dated this 5th day of March 1995.

DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.

oi650


Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1995, No 22


NZLII PDF NZ Gazette 1995, No 22





✨ LLM interpretation of page content

πŸ₯ Corrigendum to Medicines Notice

πŸ₯ Health & Social Welfare
28 February 1995
Correction, Medicines Act, Promedrol, methylprednisolone
  • DAVID SMYTH, Acting Director-General of Health

πŸ₯ Consent to Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
5 March 1995
Medicines Act, changed medicines, Tracrium, Zavedos, Tilcotil, Nitrolingual pumpspray, Derbac-M, Sandimmun-Neoral, Zocor, Lipostat, Orelox, Roferon-A
  • DAVID SMYTH, Acting Director-General of Health

πŸ₯ Consent to Distribution of New Medicines

πŸ₯ Health & Social Welfare
Medicines Act, new medicines